Your shopping cart is currently empty

Ifebemtinib (BI-853520) is an orally active and potent inhibitor of adhesion plaque kinase (FAK) (IC50=1 nM) with anti-tumour activity that inhibits globule formation and in situ tumour growth in malignant pleural mesotheliomas, and may be useful for the study of breast and ovarian cancer.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $157 | In Stock | In Stock | |
| 5 mg | $272 | In Stock | In Stock | |
| 10 mg | $409 | In Stock | In Stock | |
| 25 mg | $636 | In Stock | In Stock | |
| 50 mg | $979 | In Stock | In Stock | |
| 100 mg | $1,380 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $352 | In Stock | In Stock |
| Description | Ifebemtinib (BI-853520) is an orally active and potent inhibitor of adhesion plaque kinase (FAK) (IC50=1 nM) with anti-tumour activity that inhibits globule formation and in situ tumour growth in malignant pleural mesotheliomas, and may be useful for the study of breast and ovarian cancer. |
| Targets&IC50 | FER:900 nM, FES:1040 nM, FAK:1 nM |
| In vitro | 4T1, Py2T, and Py2T-LT cells were exposed to increasing concentrations of BI-853520 (0, 0.1, 0.5, 1, 5, and 10 μM for 4T1 cells; 1, 3, and 10 μM for Py2T and Py2T-LT cells) for 24 hours. The results demonstrate that BI-853520 reduces Y397-FAK phosphorylation in a dose-dependent and time-dependent manner[2]. |
| In vivo | In PC-3 cells, BI-853520(Ifebemtinib;0-3 μM; 2 h) resulted in a concentration-dependent reduction of the signal, with a median EC50 value of 1 nM[2]. |
| Synonyms | IN-10018, BI-853520 |
| Molecular Weight | 588.55 |
| Formula | C28H28F4N6O4 |
| Cas No. | 1227948-82-4 |
| Smiles | COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1Nc1ncc(c(Oc2cccc3CN(C)C(=O)c23)n1)C(F)(F)F |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 71.4 mg/mL (121.32 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 3.3 mg/mL (5.61 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.